trending Market Intelligence /marketintelligence/en/news-insights/trending/wTSrXE06pe-5PZv6eIKO7g2 content esgSubNav
In This List

CytomX Therapeutics chairman to resign; replacement named

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


CytomX Therapeutics chairman to resign; replacement named

CytomX Therapeutics Inc. said Hoyoung Huh would step down as chairman, effective Dec. 31.

The company appointed President and CEO Sean McCarthy to replace Hoyoung as chairman and James Meyers as a board member.

Meyers serves as a director at Arbutus Biopharma Corp., a public biopharmaceutical company. In addition, he was executive vice president of worldwide commercial operations at Gilead Sciences Inc.

South San Francisco, Calif.-based CytomX Therapeutics operates as an oncology-focused biopharmaceutical company.